Rhythm Pharmaceuticals Q4 2024 Earnings Report $51.78 +1.55 (+3.08%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Rhythm Pharmaceuticals EPS ResultsActual EPS-$0.72Consensus EPS -$0.69Beat/MissMissed by -$0.03One Year Ago EPSN/ARhythm Pharmaceuticals Revenue ResultsActual Revenue$41.83 millionExpected Revenue$38.48 millionBeat/MissBeat by +$3.35 millionYoY Revenue GrowthN/ARhythm Pharmaceuticals Announcement DetailsQuarterQ4 2024Date2/26/2025TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptRYTM Earnings History Remove Ads Rhythm Pharmaceuticals Earnings HeadlinesStifel Nicolaus Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)March 11 at 7:16 PM | markets.businessinsider.comRhythm Pharmaceuticals' (RYTM) "Overweight" Rating Reiterated at Morgan StanleyMarch 10, 2025 | americanbankingnews.comSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The markets? They're holding up—for now. But if history has taught us anything, it's this: when things feel too quiet, chaos is right around the corner.March 14, 2025 | Genesis Gold Group (Ad)Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Recommendation of "Moderate Buy" by AnalystsMarch 9, 2025 | americanbankingnews.comRhythm Pharmaceuticals assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comStifel Nicolaus Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)March 7, 2025 | americanbankingnews.comSee More Rhythm Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rhythm Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rhythm Pharmaceuticals and other key companies, straight to your email. Email Address About Rhythm PharmaceuticalsRhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.View Rhythm Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherAnalysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before Earnings Upcoming Earnings PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (3/26/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
